CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0266

Metribolone

Filed under Injectable Oils. The bureau holds 107 laboratory returns for this compound from 33 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

33 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760 A 5 10.0 9.9 10.0 21 May 2026 21 May 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 4 10.0 9.9 10.0 3 Feb 2026 16 May 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 4 10.0 9.9 10.0 16 Feb 2026 16 Jul 2026
GenScript PeptidesCASE #VI-2026-0860 A 4 10.0 9.9 10.0 26 May 2026 2 Jul 2026
Sigma-AldrichCASE #VI-2026-0829 A 4 10.0 9.9 10.0 8 Feb 2026 25 May 2026
JEEP PeptidesCASE #VI-2026-0457 A 3 10.0 9.9 10.0 16 Jan 2026 1 May 2026
Kerui PeptidesCASE #VI-2026-0626 A 3 10.0 9.9 10.0 1 Jun 2026 22 Jun 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 3 10.0 9.9 10.0 8 Dec 2025 16 Jul 2026
WuXi TIDESCASE #VI-2026-0335 A 3 10.0 9.9 10.0 4 Mar 2026 5 Jun 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 10.0 9.9 10.0 3 Apr 2026 4 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 2 10.0 10.0 10.0 27 Dec 2025 4 Jul 2026
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 6 9.9 9.9 10.0 14 Nov 2025 16 Apr 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 4 9.9 9.9 10.0 4 Feb 2026 8 Jul 2026
PolyPeptide GroupCASE #VI-2026-0143 A 4 9.9 9.9 10.0 16 Mar 2026 18 Aug 2026
AmbioPharmCASE #VI-2026-0177 A 4 9.9 9.9 10.0 4 Feb 2026 15 Aug 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 3 9.9 9.9 10.0 12 Feb 2026 20 May 2026
Hubei JianxiangCASE #VI-2026-0048 A 3 9.9 9.9 10.0 7 May 2026 12 Jul 2026
Sangon BioCASE #VI-2026-0671 A 2 9.9 9.9 10.0 23 Jan 2026 9 May 2026
QYAOBIOCASE #VI-2026-0861 A 2 9.9 9.9 10.0 5 Feb 2026 20 May 2026
BachemCASE #VI-2026-0314 A 2 9.9 9.9 9.9 19 Mar 2026 17 Apr 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 10.0 12 Jan 2026 3 May 2026
SinoPepCASE #VI-2026-0387 A 2 9.9 9.9 10.0 6 Jul 2026 26 Jul 2026
AsymchemCASE #VI-2026-0091 A 2 9.9 9.9 9.9 20 May 2026 27 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 2 9.4 9.3 9.5 25 May 2026 25 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 6 8.6 7.6 10.0 23 May 2026 23 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 7 8.4 7.5 9.0 23 May 2026 23 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 8 8.2 6.4 10.0 21 May 2026 21 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 3 7.6 6.3 8.5 24 May 2026 24 May 2026
Alpha-GenCASE #VI-2026-0905 X 3 7.0 3.6 8.8 16 Mar 2025 17 May 2026
Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 X 1 5.3 5.3 5.3 2 Jul 2025 2 Jul 2025
Richards Biotech Simply RichardsCASE #VI-2026-0307 X 1 4.3 4.3 4.3 27 Feb 2025 27 Feb 2025
Guangzhou Yuao TradingCASE #VI-2026-0787 X 1 2.1 2.1 2.1 24 Apr 2025 24 Apr 2025
Peptide ArkCASE #VI-2026-0350 X 1 1.4 1.4 1.4 25 Apr 2025 25 Apr 2025

Open any subject to view the batch-level evidence for Metribolone alone.